Skip to main content
FOXO
OTC Industrial Applications And Services

FOXO Q3: $42,678 Cash, Going Concern Doubt, Grifols Deal Slipping to 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Technology
Sentiment info
Negative
Importance info
8
Price
$0.169
Mkt Cap
$279.89K
52W Low
$0.003
52W High
$7.201
52W Position
Off High info
98% below high
Rel. Volume
Market data snapshot near publication time

Summary

FOXO reported a $101,301 Q3 profit that masks a $2.3M nine-month operating loss, with just $42,678 of cash, $17.9M of debt in default and renewed going-concern doubt. The Grifols acquisition slipped to 2027, and the Ludwig deal hinges on a Nasdaq listing and offering that would first repay $7.8M of senior notes.


Key Events · Earnings and Guidance · FOXO

  • Q3 Profit Is Accounting, Not Operating

    Net income attributable to FOXO was $101,301 for Q3 2026 versus a $1.9M loss a year earlier. The nine-month $6.8M profit includes a $9.1M reversal of stock compensation tied to forfeited founder shares, leaving roughly a $2.3M underlying loss.

  • Cash Nearly Gone, Debt All Current

    Cash fell to $42,678 at September 30, 2026 from $207,453 at December 31, 2025, against $17.9M of total debt classified as current and a $35.8M working capital deficit.

  • Going Concern Doubt Reaffirmed

    Management states substantial doubt about the ability to continue as a going concern, citing defaults on numerous promissory notes accruing $500-per-day penalties and about $3.7M of principal, penalties and interest in arrears.

  • Grifols Deal Slips to 2027, Unfunded

    The $3.5M cash purchase of four blood collection centers from Grifols Bio Supplies (plus up to $1.0M earn-out) did not close in Q3 2026. It now needs an FDA license, CLIA certification and a Miami waste permit, and FOXO says it lacks the cash to close.


Analysis · FOXO · Industrial Applications And Services

The $101,301 profit FOXO reported for the third quarter is almost entirely accounting noise. The nine-month $6.8M net income exists only because the company reversed $9.1M of stock compensation after its founder's shares were forfeited. Strip that out and the company lost about $2.3M over nine months while burning through cash. It ended September with $42,678 on hand against $17.9M of debt, all classified current, and a $35.8M working capital deficit. Management repeats that there is substantial doubt about continuing as a going concern, with many notes in default and $500/day penalties accruing. Both growth deals are unfunded and unclosed. The $3.5M Grifols blood-center purchase missed its Q3 target and now needs an FDA license, CLIA certification and cash the company does not have. The Ludwig transaction signed October 25 requires a Nasdaq listing and a public offering within 120 days, and any offering would first have to repay $7.8M of senior notes. A November 8 cyber incident adds operational risk. The equity is levered to financing outcomes, not operations.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FOXO was trading at $0.17 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $279.9K. The 52-week trading range was $0.00 to $7.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FOXO - Latest Insights

FOXO
Oct 29, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.060
Real-time Price: $0.1688 info
Change: +$0.1088 (+181%) info
Market Cap: $279.89K info
FOXO
May 28, 2026, 8:33 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.0001
Real-time Price: $0.1688 info
Change: Reverse Stock Split info
Market Cap: $279.89K info
FOXO
May 15, 2026, 11:01 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.0001
Real-time Price: $0.1688 info
Change: Reverse Stock Split info
Market Cap: $279.89K info
FOXO
Apr 20, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0001
Real-time Price: $0.1688 info
Change: Reverse Stock Split info
Market Cap: $279.89K info
FOXO
Apr 15, 2026, 12:17 PM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.0001
Real-time Price: $0.1688 info
Change: Reverse Stock Split info
Market Cap: $279.89K info